BRANFORD, Conn., Oct. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, ...

BRANFORD, Conn. - Azitra, Inc. (NYSE American:AZTR), a clinical-stage biotech company currently trading near its 52-week low of $0.68, announced positive preclinical results for its ATR-01 program ...

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced ...

Please provide your email address to receive an email when new articles are posted on . A new topical isotretinoin formula was safe and efficacious in the treatment of congenital ichthyosis, according ...

Investing.com -- Azitra Inc (NYSE:AZTR) stock surged 42.3% in premarket trading Monday following the announcement of positive preclinical data for its ATR-01 program targeting ichthyosis vulgaris, a ...

Ichthyosis features abnormal keratinization and resulting in scaling of the skin. Ichthyosis and pityriasis rubra pilaris are very difficult conditions for a child to deal with emotionally and ...

Harlequin Ichthyosis (HI) is one of the rarest and most severe congenital skin disorders in the world. This disorder affects approximately 1 in 300,000 to 500,000 births. For decades, it was ...

A Farmington-based company that was started four years ago by a group of Yale University scientists has secured $2.15 million in new financing. Azitra Inc. received the financing from a combination of ...

ATR-01, which uses a filaggrin-secreting strain of S. epidermidis, is in preclinical development for ichthyosis vulgaris Preclinical data show production of active, functional filaggrin delivered ...